New liposomal cocktail takes on pancreatic cancer in major trial
NCT ID NCT07238283
First seen Nov 20, 2025 · Last updated May 18, 2026 · Updated 26 times
Summary
This phase 3 trial compares a new chemotherapy combination (irinotecan liposome plus oxaliplatin, 5-FU, and calcium folinate) against the current standard (nab-paclitaxel plus gemcitabine) for people with metastatic pancreatic cancer who have not yet received treatment. The study aims to see if the new combo helps patients live longer. About 662 adults with good performance status and measurable tumors will participate at multiple centers.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FIRST-LINE TREATMENT OF METASTATIC PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Peking Union Medical College Hospital, Chinese Academy of Medical Sciences
RECRUITINGBeijing, Beijing Municipality, 100730, China
Contact
Contact
Conditions
Explore the condition pages connected to this study.